|13.76|| +0.05 / +0.36%|
RedHill Biopharma Ltd. is a biopharmaceutical company. Primarily, it is focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. Its current pipeline of proprietary products includes: (i) RHB-105-an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study; (ii) RHB-104-an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study and an ongoing proof-of-concept Phase IIa study for multiple sclerosis; (iii) BEKINDA (RHB-102)-a once-daily oral pill formulation of ondansetron with an ongoing Phase III study in the U.S. for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; (iv) RHB-106-an encapsulated bowel preparation licensed to Salix Pharmaceuticals Ltd.; (v) YELIVA (ABC294640)-a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications; (vi) MESUPRON-a Phase II-stage first-in-class uPA inhibitor, administered by oral capsule, targeting gastrointestinal and other solid tumors; (vii) RP101 is a Phase II-stage first-in-class Hsp27 inhibitor, administered by oral tablet, targeting pancreatic and other gastrointestinal cancers; (viii) RIZAPORT (RHB-103)-an oral thin film formulation of rizatriptan for acute migraines and (ix) RHB-101-a once-daily oral pill formulation of the cardio drug carvedilol. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.
|Dror Ben-Asher||Chairman & Chief Executive Officer|
|Gilead Raday||Chief Operating Officer|
|Micha Ben-Chorin||Chief Financial Officer|
|Reza Fathi||Senior Vice President-Research & Development|
|Adi Frish||Senior VP-Business Development & Licensing|